Key Points
- CryoPort CFO Robert Stefanovich sold 169,427 shares on June 4 at an average price of $16.27, totaling about $2.76 million. After the sale, he still held 109,850 shares, representing a 60.67% reduction in his position.
- The company’s latest earnings report showed EPS of -$0.23, missing analysts’ expectations, though revenue of $47.8 million came in above estimates. Analysts now expect CryoPort to post -0.85 EPS for the full year.
- Despite the insider selling, Wall Street sentiment has improved, with several firms raising price targets and the stock holding a consensus rating of “Moderate Buy.” CryoPort shares recently traded near $15.48, close to their 52-week high of $16.73.
CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) Director Ramkumar Mandalam sold 23,214 shares of the business's stock in a transaction on Monday, June 8th. The stock was sold at an average price of $15.44, for a total transaction of $358,424.16. Following the completion of the transaction, the director directly owned 67,894 shares in the company, valued at $1,048,283.36. This trade represents a 25.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
CryoPort Stock Performance
CYRX stock opened at $15.48 on Tuesday. CryoPort, Inc. has a one year low of $6.16 and a one year high of $16.73. The company's fifty day moving average price is $11.89 and its 200-day moving average price is $10.17. The company has a market capitalization of $780.19 million, a PE ratio of 11.47 and a beta of 1.90.
CryoPort (NASDAQ:CYRX - Get Free Report) last released its earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The company had revenue of $47.80 million during the quarter, compared to analysts' expectations of $44.86 million. On average, research analysts predict that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.
Institutional Investors Weigh In On CryoPort
A number of hedge funds have recently bought and sold shares of CYRX. Basepoint Wealth LLC bought a new position in CryoPort during the fourth quarter valued at $34,000. Tower Research Capital LLC TRC increased its position in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock valued at $44,000 after acquiring an additional 4,375 shares during the last quarter. AlphaQuest LLC bought a new position in CryoPort during the third quarter valued at $79,000. Quadrature Capital Ltd bought a new position in CryoPort during the fourth quarter valued at $97,000. Finally, Corient Private Wealth LLC bought a new position in CryoPort during the fourth quarter valued at $113,000. Hedge funds and other institutional investors own 92.90% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the stock. Craig Hallum upped their price target on shares of CryoPort from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, June 3rd. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a research note on Monday. KeyCorp upped their price target on shares of CryoPort from $15.00 to $17.00 and gave the company an "overweight" rating in a research note on Wednesday, May 20th. Needham & Company LLC upped their price target on shares of CryoPort from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Tuesday, May 5th. Finally, BTIG Research upped their price target on shares of CryoPort from $15.00 to $17.00 and gave the company a "buy" rating in a research note on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, CryoPort presently has a consensus rating of "Moderate Buy" and an average price target of $15.11.
View Our Latest Stock Analysis on CryoPort
CryoPort Company Profile
(
Get Free Report)
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
